New Italian study below [1].
Some might rememer my series of posts on inflammation. The first was "Inflammation. [1] Neutrophil-to-Lymphocyte Ratio [NLR]" [2].
The gist of the series was simply this: while countless studies now see subclinical inflammation markers as having prognostic value, I see them as pointers for intervention.
Chronic inflammation, whether it be associated with cancer or conditions such as rheumatoid arthritis, is always due to chronic activation of nuclear factor-kappB [NF-kB]. NF-kB creates a large number of cell survival proteins, but notably, the COX/LOX enzymes that act on the arachidonic acid in the cell to create inflammatory metabolites that promote cell division.
We can take the heat out of these medical conditions by inhibiting NF-kB. All of the polyphenols I have written about are NFkB inhibitors.
Tom Gilmore at Boston U. has a nice NF-kB site. It contains a page on inhibitors [3].
How can we monitor success? By re-testing the markers & increasing dosage if necessary. Elimination of inflammation will extend life.
In the new study:
"... analyses showed that NLR, PLR, and ELR ... were significantly associated with upgrading (ORs ranging from 2.13 to 4.13)"
NLR is neutrophil to lymphocyte ratio (see [2])
PLR is platelets to lymphocyte ratio (see [4])
ELR is eosinophil to lymphocyte ratio
Inflammation = fast-track disease.
There isn't a lot about PLR in the PCa literature, but here is a meta-analysis from October [4]:
"This meta-analysis showed that a high PLR was correlated with poor DFS {disease-free survival} and OS {overall survival} in patients with prostate cancer."
***
Other old posts:
"Inflammation. [2] Albumin & C-Reactive Protein [CRP]" [5]
"Inflammation. [3] SedRate, Fibrinogen, IL-6, TNFalpha." [6]
"Inflammation. [4] How to Change the Numbers" [7]
-Patrick
[1] ncbi.nlm.nih.gov/pubmed/304...
[2] healthunlocked.com/advanced...
[3] bu.edu/nf-kb/physiological-...
[4] ncbi.nlm.nih.gov/pmc/articl...
[5] healthunlocked.com/advanced...